Sep 2026· Progress in Biophysics and Molecular Biology· pp.
101949
· 1 citation· 229 references
Medicine
TL;DR
This review critically examines pyroptosis-TIME crosstalk in TNBC, prioritizing TNBC and breast cancer evidence while using non-breast cancer findings only as mechanistic comparators when they clarify conserved inflammasome or gasdermin biology.
Abstract
Triple-negative breast cancer (TNBC) remains an aggressive breast cancer subtype marked by molecular heterogeneity, immune evasion, limited actionable targets, and variable responses to immune-based therapy. Pyroptosis, a gasdermin-mediated inflammatory form of regulated cell death, may link tumor-cell injury to remodeling of the tumor immune microenvironment (TIME). However, its role in TNBC should not be interpreted as uniformly antitumor. Instead, pyroptotic signaling represents a context-dependent inflammatory process shaped by inflammasome activation, gasdermin cleavage, cellular source, subcellular localization, cytokine release, hypoxia, stromal restriction, immune-cell composition, and membrane-repair capacity. Transient and spatially restricted tumor-cell pyroptosis may support antigen release, dendritic-cell activation, and cytotoxic lymphocyte recruitment, whereas persistent or poorly localized activation may amplify myeloid inflammation, fibrosis, immune exclusion, tissue injury, and inflammatory toxicity. This review critically examines pyroptosis-TIME crosstalk in TNBC, prioritizing TNBC and breast cancer evidence while using non-breast cancer findings only as mechanistic comparators when they clarify conserved inflammasome or gasdermin biology. We summarize canonical and non-canonical inflammasome pathways, gasdermin regulation, apoptosis-pyroptosis crosstalk, immune-subset remodeling, hypoxic and stromal constraints, and preclinical therapeutic approaches aimed at controlled pyroptosis induction. By distinguishing direct TNBC evidence from extrapolation and emphasizing safety, biomarkers, and validation gaps, this review provides an evidence-graded framework for evaluating pyroptosis as a potential but still investigational immunomodulatory strategy in TNBC.
Clinical translation remains limited by dependence on retrospective transcriptomic datasets, insufficient mechanistic validation, lack of standardized assays, and scarce prospective clinical evidence, but pyroptosis-associated lncRNAs represent a promising link between tumor progression and immune regulation, with cons...
Chou-Yi Hsu, Bilal Abdulmajeed Mukhlif, O. Nematov et al.· Cell Cycle· 0 citations
This review synthesizes newly emerging mechanisms of TAM-mediated immunotherapy resistance, including spatial heterogeneity, stromal-vascular remodeling, and exosomal crosstalk, with the latest clinical advances in macrophage-directed immunotherapies.
Xiao-Feng Cui, Xue-Rui Wang, Nan Jiang et al.· Frontiers in Immunology· 0 citations
This framework may guide more precise intervention along the RCD–macrophage axis and evaluate nanomedicine strategies that coordinate tumor-selective RCD with macrophage regulation while emphasizing limitations in cell-type specificity, safety, patient selection and clinical evidence.
Xiao-Tang Duan, Pei-Ling Ma, X. Ao et al.· Frontiers in Immunology· 0 citations
Neutrophil extracellular trap formation (NETosis) has emerged as a pivotal regulator of the tumor immune microenvironment and a key determinant of response to cancer immunotherapy. NETs—web-like chromatin fibers decorated with histones, citrullinated histone H3, myeloperoxidase, neutrophil elastase, and matrix metallop...
Chung-Wen Kuo, H. Chiou, Shih-Yu Huang et al.· International Journal of Mol...· 1 citation
It is proposed that rational combinations of STING agonists with Fc-engineered PD-L1/PD-L2-targeting antibodies, guided by dynamic and spatial biomarkers, could overcome resistance to conventional immune checkpoint blockade in tumors with minimal T-cell infiltration but targetable tumor vasculature.
Akash R. Boda, E. Bolli, A. Salameh et al.· Frontiers in Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.